期刊文献+

生长抑素受体介导的肿瘤靶向治疗 被引量:3

Somatostatin Receptor-Mediated Tumor-Targeted Therapy
原文传递
导出
摘要 许多肿瘤,如神经内分泌肿瘤、甲状腺癌、乳腺癌等能高表达生长抑素受体,从而为生长抑素及其类似物的治疗提供了靶点。生长抑素受体介导的肿瘤靶向治疗主要包括放射性核素治疗、放射导向手术治疗、细胞毒素治疗和溶瘤病毒治疗。目前,生长抑素受体介导的放射性核素治疗已应用于神经内分泌肿瘤,尤其在胃肠胰神经内分泌肿瘤的诊断和治疗中占据重要地位。另外,生长抑素受体介导的放射导向手术治疗、细胞毒素治疗和溶瘤病毒治疗的潜在价值也越来越引起研究者们的重视。本文通过查阅近五年来关于生长抑素受体介导的肿瘤靶向治疗的国内外文献,综述了生长抑素受体介导的肿瘤靶向治疗的最新研究进展。 : A lot of tumors, such as neuroendocrine neoplasms, thyroid cancer and breast cancer usually can over express somatostatin receptors. Thus somatostatin and its analogues can target these tumors and exert anti-secretory activity and anti-neoplastic activity through binding to the somatostatin receptors on the surface of tumor cells. Somatostatin receptor-mediated tumor-targeted therapy mainly includes radionuclide therapy, radioguided surgery therapy, cytotoxic therapy and oncolytic virotherapy. Nowadays, somatostatin receptor-mediated radionuclide therapy have been put into use for the treatment of neuroendocrine neoplasms, especially playing an important role in the diagnosis and therapy of gastroenteropancreatic neuroendocrine neoplasms. Moreover, Somatostatin receptor-mediated radioguided surgery therapy, cytotoxic therapy and oncolytic virotherapy are also attracting more and more attention from researchers with the potential values in the treatment of various tumor types. In order to provide gist for the clinical applications of somatostatin receptor-mediated tumor-targeted therapy, the present article makes a review about up-to-date research advances of somatostatin receptor-mediated tumor-targeted therapy, informed by literatures about somatostatin receptor-mediated tumor-targeted therapy published at home or abroad in the past five years.
出处 《现代生物医学进展》 CAS 2016年第14期2793-2796,共4页 Progress in Modern Biomedicine
基金 湖南省自然科学基金项目(12JJ9030)
关键词 生长抑素 生长抑素受体 生长抑素类似物 肿瘤靶向治疗 Somatostatin Somatostatin receptors Somatostatin analogous Tumor-targeted therapy
  • 相关文献

参考文献42

  • 1Sliwifi ska-mosson M, Vesely, M, Milnerowicz H. The clinical significance of somatostatin in pancreatic diseases[J]. Ann Endocrinol (Pads), 2014, 75(4): 232-240.
  • 2Martin-grace J, Tamagno G. Somatostatin analogs in the medical management of occult bleeding of the lower digestive tract [J]. Gastroenterol Res Pratt, 2015:702921.
  • 3Rai U, Thrimawithana TR, Valery C, et al. Therapeutic uses of somatostatin and its analogues: Current view and potential applications[J]. Pharmacol Ther, 2015, 152:98-110.
  • 4Taieb D, Garfigue P, Bardie s M, et al. Application and Dosimetric Requirements for Gallium-68-1abeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors[J]. PET Clin, 2015, 10(4): 477-486.
  • 5Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors [J]. J Natl Compr Cane Netw, 2015, 13(1): 109-117.
  • 6Chalabi M, Duluc C, Caron P, et al, Somatostatin analogs: does pharmacology impact antitumor efficacy? [J]. Trends Endocrinol Metab, 2014, 25(3): 115-127.
  • 7Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, et al. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16 [J]. Gastroenterology, 2015, 148(7): 1452-1465.
  • 8Leiszter K, Sipos F, Galamb O, et al. Promoter hypermethylation- related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer [J]. PLoS One, 2015, 10 (2): e0118332.
  • 9Hennigs JK, Mu Uer J, Adam M, et al. Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse[J]. PLoS One, 2014, 9(7): e100469.
  • 10Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers [J]. J Clin Oncol, 2011, 29(17): 2416-2423.

二级参考文献95

  • 1岳欣,顾锋,夏维波,萧新华,李梅,邢小平,曾正陪,向红丁,连小兰,伍学焱.胰岛素瘤的术前定性及定位诊断99例分析[J].中国实用内科杂志:临床前沿版,2006,26(11):1795-1797. 被引量:16
  • 2Modlin IM, Kidd M, Pfragner R, et al. The functional character- ization of normal and neoplastic human enterochromaffin cells [J]. J C/in Endocrinol Metab,2006, 91 (6) :2340-2348.
  • 3Yao JC, Hassan M, Phan A, et al. One hundred years after "caz'cinoid" : epidemiology of and prognostic factors for neuroen- docrine tumors in 35,825 cases in the United States[ J]. J Clin Oneo1.2008.26 ( 18 ) :3063 - 3072.
  • 4Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors [ J ]. Cancer,2003,97 (4) :934 - 959.
  • 5ho T, Sasano H, Tanaka M, et al. Epidemiological study of gas- troenteropancreatic neuroendocrine tumors in Japan [ J ]. J Gas- troentero1,2010,45 ( 2 ) : 234 - 243.
  • 6Wang YH, Lin Y, Xae L, et al. Relationship between clinical characteristics and survival of gastroenteropancreatic neuroendo- crine neoplasms: A single-institution analysis (1995-2012) in South China[ J] BMC Endocr Disord,2012 ,12 :30.
  • 7Oberg KE. Gastrointestinal neuroendocrine tumors[ J]. Ann On- col ,2010,21 ( Suppl 7 ) : vii 72 - vii 80.
  • 8Jensen RT, Niederle B, Mitry E, et al. Gastrinoma (duodenal and pancreatic ) [ J ]. Neuroendocrinology, 2006,84 ( 3 ) : 173 - 182.
  • 9Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [ 1111n-DTPA-1)-Phel -and [ 123I-Tyr3 ]-octreotide: the Rotterdam experience with more than 1, 000 patients[J]. Eur J Nucl Med,1993,20(8) :716 -731.
  • 10Lebtahi R, Cadiot G, Sarda L, et al. Clinical impact of soma- tostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors [ J]. J Nucl Med, 1997,38 (6) :853 - 858.

共引文献100

同被引文献31

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部